Imugene Ltd has dosed the first patient in the BTKi combination cohort of its Phase 1b azer-cel study, expanding its clinical program into a global market worth about $12 billion by 2025. The patient, treated in Texas, has mantle cell lymphoma and had previously failed BTKi therapy. Azer-cel is an off-the-shelf allogeneic CAR T cell therapy aimed at advanced blood cancers with high unmet needs. This new cohort tests azer-cel combined with BTKi to evaluate safety and early efficacy in patients who relapsed after prior BTKi treatment, potentially broadening clinical applications and supporting future partnerships. The study is ongoing across 15 sites in the US and Australia, with updates expected as more data matures.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
XRP surged about 4% to $1.11 following a broader crypto market rebound triggered by softer U.S. inflation data. Technical signals suggest a bullish inverse head and shoulders pattern, with potential for a 20% price increase if XRP breaks the $1.12–$1...
Revolut has received preliminary approval from Dubai's Virtual Assets Regulatory Authority to offer cryptocurrency services in the UAE, including broker-dealer, asset management, and exchange functions. This approval allows UAE customers to trade and...
Rotork PLC has accepted a £4.1 billion takeover bid from Swiss engineering group ABB, offering shareholders 506p per share, a 73% premium over the previous closing price. The acquisition will enhance ABB's industrial automation business by adding Rot...
Alexandria Real Estate Equities (ARE) is struggling with oversupply and vacancy rates exceeding 30% in key life science markets like Boston, San Francisco, and San Diego. This has caused an 80% decline in its stock price from its peak. The company's ...
